Spots Global Cancer Trial Database for mosunetuzumab
Every month we try and update this database with for mosunetuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | NCT04313608 | B-cell Lymphoma | Glofitamab Gemcitabine Oxaliplatin Mosunetuzumab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | NCT05205252 | Relapsed Hemato... Refractory Hema... | Tazemetostat Tafasitamab Lenalidomide Acalabrutinib Daratumumab (In... Mosunetuzumab Daratumumab (Su... Hyaluronidase-F... Pomalidomide Dexamethasone 2... | 18 Years - | Ipsen | |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT05091424 | Chronic Lymphoc... | Mosunetuzumab Tocilizumab Venetoclax | 18 Years - | Hoffmann-La Roche | |
| A Study of Mosunetuzumab in People With Follicular Lymphoma | NCT05389293 | Follicular Lymp... Lymphoma | Mosunetuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT06015880 | Diffuse Large B... High Grade B-Ce... Transformed Ind... | Biospecimen Col... Computed Tomogr... Lenalidomide Mosunetuzumab Polatuzumab Ved... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | NCT06249191 | Diffuse Large B... High Grade B-Ce... | Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Cyclophosphamid... Doxorubicin Echocardiograph... Etoposide Magnetic Resona... Mosunetuzumab Multigated Acqu... Positron Emissi... Prednisone Vincristine | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | NCT05615636 | Hodgkin Lymphom... B-Cell Lymphoma Relapsed B-cell... | Mosunetuzumab Polatuzumab ved... Tafasitamab Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | NCT03677141 | B-cell Non-Hodg... | Mosunetuzumab Polatuzumab Ved... Rituxumab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | NCT05169658 | Non-Hodgkin Lym... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent B-Cell... Marginal Zone L... Recurrent Extra... Refractory Extr... | Mosunetuzumab Obinutuzumab Polatuzumab Ved... | 18 Years - | University of Washington | |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT05633615 | Diffuse Large B... Grade 3b Follic... Primary Mediast... Recurrent Diffu... Refractory Diff... Transformed Fol... Transformed Mar... | Axicabtagene Ci... Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Lisocabtagene M... Mosunetuzumab Patient Observa... Polatuzumab Ved... Positron Emissi... Tisagenlecleuce... | 18 Years - | SWOG Cancer Research Network | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | NCT05260957 | Refractory Non-... Relapsed Non Ho... Aggressive Non-... | Mosunetuzumab Polatuzumab CAR-T Cell Ther... | 18 Years - 80 Years | University of Miami | |
| Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries | NCT05849857 | Lymphoma, Folli... | Mosunetuzumab | 18 Years - | Oslo University Hospital | |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | NCT05615636 | Hodgkin Lymphom... B-Cell Lymphoma Relapsed B-cell... | Mosunetuzumab Polatuzumab ved... Tafasitamab Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 | NCT06284122 | Follicular Lymp... | Mosunetuzumab Lenalidomide Rituximab Obinutuzumab Cyclophosphamid... Doxorubicin Vincristin Prednisone Rituximab Obinutuzumab Bendamustin | 18 Years - | The Lymphoma Academic Research Organisation | |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT06015880 | Diffuse Large B... High Grade B-Ce... Transformed Ind... | Biospecimen Col... Computed Tomogr... Lenalidomide Mosunetuzumab Polatuzumab Ved... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma | NCT05886036 | Nodular Lymphoc... Recurrent Nodul... Refractory Nodu... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Fludeoxyglucose... Mosunetuzumab Positron Emissi... Rituximab Rituximab and H... | 18 Years - | National Cancer Institute (NCI) | |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | NCT06249191 | Diffuse Large B... High Grade B-Ce... | Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Cyclophosphamid... Doxorubicin Echocardiograph... Etoposide Magnetic Resona... Mosunetuzumab Multigated Acqu... Positron Emissi... Prednisone Vincristine | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | NCT06337318 | Classic Follicu... Follicular Lymp... | Biospecimen Col... Computed Tomogr... Mosunetuzumab Positron Emissi... Rituximab Rituximab and H... | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma | NCT04712097 | Relapsed or Ref... | Mosunetuzumab Lenalidomide Rituximab Tociluzumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 | NCT06284122 | Follicular Lymp... | Mosunetuzumab Lenalidomide Rituximab Obinutuzumab Cyclophosphamid... Doxorubicin Vincristin Prednisone Rituximab Obinutuzumab Bendamustin | 18 Years - | The Lymphoma Academic Research Organisation | |
| A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | NCT05171647 | Non-Hodgkin Lym... | Mosunetuzumab Polatuzumab ved... Tocilizumab Rituximab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT05672251 | Recurrent Diffu... Recurrent Grade... Recurrent High ... Recurrent Prima... Recurrent Trans... Recurrent Trans... Refractory Diff... Refractory Grad... Refractory High... Refractory Prim... Refractory Tran... Refractory Tran... | Biopsy Biospecimen Col... Computed Tomogr... Loncastuximab T... Mosunetuzumab Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma | NCT05886036 | Nodular Lymphoc... Recurrent Nodul... Refractory Nodu... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Fludeoxyglucose... Mosunetuzumab Positron Emissi... Rituximab Rituximab and H... | 18 Years - | National Cancer Institute (NCI) | |
| Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | NCT05994235 | Follicular Lymp... | Mosunetuzumab Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | NCT05410418 | Lymphoma, Folli... Follicular Lymp... | Mosunetuzumab Polatuzumab ved... | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
